Impact of Licensing Pressure on Drug Pricing Limited, Study Finds

The recent analysis by Competition Dynamics indicates that the strategy of compelling patent holders of Orange Book drugs to authorize additional licensing might not significantly influence drug pricing. This approach, while aimed at enhancing market competition, may only have a limited effect and its potential drawbacks on pharmaceutical innovation should be carefully considered. As detailed in the Law360 article, researchers emphasize a balanced approach in addressing these complex legal and economic issues inherent in the pharmaceutical industry.